Kalytera Therapeutics, Inc.
Profile
Mailing Address: 500 S. Sepulveda Blvd., Suite 212
Manhattan Beach, California
90266
Head Office Address: 500 S. Sepulveda Blvd., Suite 212
Manhattan Beach, California
90266
Contact Name: Robert Farrell Principal Regulator: British Columbia
Business e-mail address: rfarrell@kalytera.co Short Form Prospectus Issuer: Yes
Telephone Number: 415 218-3900 Reporting Jurisdictions: British Columbia, Alberta, Ontario
Fax Number: Stock Exchange: TSX Venture
Date of Formation: Oct 15 2004 Stock Symbol: KALY
Jurisdiction Where Formed: British Columbia Auditor: Kost Forer Gabbay & Kasierer
Industry Classification: consumer products - biotechnology/pharmaceuticals General Partner:
CUSIP Number: 48349P Transfer Agent: TMX Trust Company
Financial Year-End: Dec 31 Size of Issuer (Assets): $5,000,001 to $25,000,000


View This Company's Documents